You are here: Industry Insights > tumor

News List

2025 Q1: Oncology Business Competition Among MNCs Xiaobin
June 04, 2025
How did MNCs fare in the oncology field during Q1 of this year?
A Record High! A Review of Blockbuster New Drugs in China in 2024, with the Number of Innovative Drugs Reaching New Heights! Sophia
January 23, 2025
In 2024, China's pharmaceutical field thrived. NMPA approved 220 new drugs, including 46 Class 1 innovative ones with anti-tumor drugs being the most. New anti-tumor drugs offered hope, and the R&D environment will keep improving.
Golden Pen Award | Research Progress on the Application of Exosomes in Drug Delivery Xiaonisha
September 02, 2025
Exosomes are specific membrane vesicles secreted by various types of cells under normal or pathological conditions, playing a vital role in intercellular communication and exchange of information.
Golden Pen Award | The Current Status of Application of Biomembrane Nanocarrier Drug Delivery Systems in Tumor Immunotherapy Xiaonisha
August 27, 2025
In recent years, the excellent biocompatibility, modifiability, and low immunogenicity of biomembrane nanosystems have significantly advanced the development of tumor immunotherapy.
Astragalus Membranaceus Processing and Its Development and Application Prospects Xiaonisha
August 20, 2025
Astragalus membranaceus is the dried root of the leguminous plant Astragalus membranaceus var. mongholicus or Astragalus membranaceus (A. membranaceus).
The Pharmacological Effects and Application Prospects of Puerarin Xiaonisha
August 15, 2025
Puerarin, also known as Puerarin, is a natural isoflavone C-glycoside and the key component responsible for the medicinal effects of kudzu.
Preparation of Cell Membrane Biomimetic Drug Delivery Systems and Their Advantages in Tumor Therapy Xiaomichong
July 23, 2025
With the development of nanomaterials, the application of nanocarriers has become increasingly common in medical research, especially in the fields of drug delivery and gene delivery.
The Classification of Sesquiterpene Compounds and Their Research Progress Xiaomichong
May 23, 2024
Terpenoids are an important part of natural organic compounds, and there are currently more than 50,000 reported terpenoid structures.
Competitive Landscape of the New Drug Target Nectin-4 in China Yefenghong/PharmaSources
May 22, 2023
Araris Biotech AG announced on April 17 that it will acquire ARS Pharmaceutical's Nectin-4 antibody. Araris Biotech intends to use the acquired Nectin-4 antibody to develop differentiated Nectin-4 ADCs using its proprietary linker technology.
A New Target in ADC: Nectin-4 PharmaSources/Yefenghong
September 14, 2021
Recently, the application for clinical trail of Mabwell's ADC drug (9MW2821) targeting Nectin-4 has been accepted by NMPA. It is the first time that domestic enterprise enters the IND stage with the same target drug.